| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 157.36 | 50.5% | 12.0% |
| Total Income | 162.43 | 49.6% | 12.8% |
| Expenditure | 130.06 | 30.9% | 9.5% |
| PBT | 32.37 | 75.8% | 28.0% |
| Net Profit | 22.75 | 76.6% | 25.9% |
| OPM | 35.12% | 14.12pp | 14.11pp |
| NPM | 14.01% | 16.23pp | 1.47pp |
| EPS | 3.93 | 82.0% | 27.2% |
Bookings surge 120%, but revenue lags; execution risk high
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met H1 bookings aspirations and revenue targets, but sequential softness in Q2 and margin compression vs. normalized guidance (22-25%) suggest execution headwinds.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong bookings momentum (₹1,338 Cr H1, 120% YoY) and upward guidance (35-40%→70-75% FY27 growth) are offset by a critical conversion gap: realized revenue +12% YoY does not match bookings growth, and Q2 revenue fell 50.5% sequentially. The core risk is execution—whether management can convert its swollen order book into revenue within the promised timeframe without margin dilution.
₹157.4 Cr
Revenue · +12% YoY₹22.7 Cr
Reported PAT · +25.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹157 Cr, PAT ₹23 Cr with 25% YoY growth
METDelivered ₹157.4 Cr revenue, ₹22.7 Cr PAT, 25.9% YoY growth
H1 bookings ₹1,338 Cr, 120% YoY; Q2 bookings ₹906 Cr (2x+ QoQ)
UnverifiedNot disclosed in filed result; bookings are advance indicators, not revenue
Revenue 12% YoY, PAT +25% YoY in Q2 with strong margins
METDelivered 12% revenue growth, 25.9% PAT growth, 14% NPM (below mgmt's 22-25% EBITDA guidance normalized expectation)
FY27 bookings guidance upward from 35-40% to 70-75% YoY growth
METMgmt explicitly revised on call: ₹2,100-2,200 Cr (35-40%) → ₹2,600-2,700 Cr (70-75%)
Strong sequential momentum with Q1 performance carrying forward
MISSQ2 revenue -50.5% QoQ, PAT -76.6% QoQ; Q1 was ₹318 Cr revenue, ₹97 Cr PAT (calculated from H1 totals)
Earnings quality
What changed since the last call
FY27 bookings guidance revised up
UpgradePrior 35-40% growth (₹2,100-2,200 Cr) → now 70-75% growth (₹2,600-2,700 Cr). Driven by Sylva, new MMR launches, Sarjapur momentum.
GDV addition target expanded
UpgradeNow targeting ₹4,000-5,000 Cr GDV addition in FY27 vs prior ₹4,000-5,000 Cr original guidance. BD locked at ₹3,100 Cr (Sep 2026), aiming for 4k-5k by FY27-end.
Regional contribution shifted
NewBengaluru now 50% of H1 sales (vs 30% prior year); crossed ₹600 Cr market milestone for first time. MMR expansion a new strategic push.
Revenue conversion lagged bookings
DowngradeQ2 bookings ₹906 Cr but revenue ₹157 Cr; H1 bookings ₹1,338 Cr but revenue ₹475 Cr. Lag is 2.8x in H1, suggesting long project execution cycle or booking-revenue mismatch.
The Q&A
Analysts pressed hard on three fronts: (1) margin sustainability given cost inflation and new BD spend—Priyash Kapoor deflected, citing 22-25% guidance as normalized; (2) capex requirements for ₹4-5k Cr GDV—Kapoor avoided specifics, saying 'doubled vs prior year' but no absolute number; (3) execution on concurrent launches—mostly answered with confidence on project pipelines and operational discipline. Tone was defensive on margins but buoyant on growth.
Guidance revision rationale — Jainam Shah, Equirus Securities
PartialSylva in Bengaluru, two MMR projects, and Sarjapur are the drivers. On margins, current performance is strong due to project mix (Q1 one large project); normalized guidance is 22-25%. Price growth and cost control help, but we remain cautious on cost escalation.
Business development capex — Harsh Pathak, Motilal Oswal Financial Services
PartialWe are doubling construction spend vs prior year, targeting ₹1,000 Cr annual outflow for land. Debt/equity at 0.26, sufficient HDFC lines, OCF generation funds growth without material leverage increase.
Project launch execution — Amit Srivastava, 360 ONE Capital
AnsweredSylva took ~7-8 months for approval, Sarjapur ~9 months. We've learned to streamline design approval. Pricing is premium positioning (₹2.5-5 Cr in Mumbai range) with competitive edge in product and location. We maintain 25-40% inventory each market for diversification.
Revenue growth sustainability — Surender Singh, My Equity Sherpa
AnsweredIt's a reflection of our project portfolio mix and cash-flow generation. Collections are strong (₹418 Cr in Q2, 77% YoY growth). OCF is a better indicator of business health. Our project completion cycle is 3-5 years; presales will convert to revenue gradually.
Capital allocation discipline — Deepak Purswani, SVAN Investment
AnsweredWe have a clear 25% IRR hurdle for all deals. Portfolio is 70-30 JD to outright; this constrains leverage. Regional leadership now in place. We believe 30% medium-term growth is achievable without diluting returns or balance-sheet health.
Presales mix and sustenance sales — Jainam Shah, Equirus Securities
AnsweredThis year presales ~2x of last year. We're tracking INR200 Cr quarterly from sustenance (vs INR300 Cr H1 2024). Launching in all 3 cities now; sustenance will grow in absolute terms but as % of total, new launches will dominate. We're targeting structured sustenance sales, moving away from lumpy one-offs.
Guidance
FY27 bookings 70-75% YoY (₹2,600-2,700 Cr); GDV addition ₹4,000-5,000 Cr
HighUpward revision from 35-40% (₹2,100-2,200 Cr). New launches (Sylva, Sarjapur, 2 MMR) underpin. BD locked ₹3,100 Cr (Sep 2026); targeting ₹4k-5k by FY27-end.
Revenue conversion lag expected to persist 12-18 months
MediumCurrent lag: H1 bookings ₹1,338 Cr vs revenue ₹475 Cr (2.8x). Project cycle 3-5 years; presales convert gradually. Near-term revenue constrained by project mix.
EBITDA margin 22-25%; implies PAT margin 18-22% medium-term
MediumCurrent Q2 EBITDA margin 28.7%, PAT margin 14.4%. Management says current strength temporary (one project in Q1). Price growth in new launches offset by cost inflation and BD spend.
BD spend ~₹1,000 Cr annually for land acquisition; construction spend doubled vs prior year
LowNo absolute capex number given. Priyash Kapoor stated doubling but avoided specifics. Estimated ₹1,500-2,000 Cr annual capex range on stated BD spend. OCF generation expected to fund growth; net debt to stay under 0.30.
Risks the call surfaced
Revenue conversion lag
HighBookings growth (120% YoY H1) far exceeds revenue growth (12% YoY Q2). H1 gap is 2.8x. If project cycle stretches or approvals delay, revenue could miss guidance.
Project execution risk
HighFour major launches underway (Sylva, Sarjapur, 2 MMR projects) in concurrent execution. Any delay impacts presales and revenue recognition; multiple concurrent P&Ls means resource constraints.
Customer concentration
MediumSylva (₹500+ Cr, ~60% of Bengaluru inventory by value) and Sarjapur (~₹470 Cr) represent lumpy presales concentration. Underperformance in either would materially impact H2 FY27 bookings.
Margin compression risk
MediumCurrent H1 EBITDA margin 41.5%, PAT margin 25.3% well above guided 22-25% EBITDA. Q1 benefited from one large project; normalized margins will be lower. Cost inflation and new BD spend could pressure further.
Leverage and capital discipline
MediumRapid BD acceleration (targeting ₹4-5k Cr GDV addition) + construction spend doubled could increase leverage. Debt/equity at 0.26 appears safe but trajectory matters if bookings conversion slows.
Management
Score 7/10. Clear on strategy and market opportunity, but defensive on specifics (capex, exact margin timeline). Deflects on hard numbers under analyst pressure. Strong track record on presales growth (120% H1) and operational capabilities (launches on time, cost control). But sequential revenue decline Q2 suggests execution friction.
1 · Q3 FY27 (Oct-Dec 2026)
MMR project launches (2 projects, ₹2,200-2,500 Cr pipeline); Bengaluru Sarjapur and additional projects
2 · Q4 FY27 (Jan-Mar 2027)
Revenue recognition from new launches + Ahmedabad/Bengaluru sustenance sales ramp
3 · FY28 (Apr 2027+)
Scale to ₹3-5 Cr annual presales/bookings on multi-city footprint; 4th market expansion decision
The core risk is execution—whether management can convert its swollen order book into revenue within the promised timeframe without margin dilution.
The ₹863 Crore Gap: Can Arvind Convert Bookings Into Revenue?
Management upgraded bookings guidance to 70–75% growth (₹2,600–2,700 Cr), but H1 revealed a critical tension: ₹1,338 Cr in bookings yet only ₹475 Cr in revenue. The quarter tests whether launches convert as promised.
₹1,338 Cr
+120% YoY
₹475 Cr
+96% YoY
₹863 Cr
2.8x ratio
₹157.4 Cr
-50.5% QoQ
The headline reads like a blowout: H1 bookings surge 120% year-over-year, Arvind Sylva books ₹500+ crore in 30 days, management upgrades full-year guidance to 70–75% bookings growth. But dig into the revenue side and a different story emerges. H1 realized revenue was ₹475 crore—up 96% YoY but only 35.5% of the bookings generated in the same period. Q2 specifically seized ₹906 crore in new bookings yet delivered just ₹157.4 crore in revenue, a -50.5% sequential drop. The quarter forces a reckoning: are bookings the leading indicator of sustainable growth, or is the company accumulating future liabilities?
Reconciling the gap
Management's defense: project cycle of 3–5 years. Presales (bookings) are advance indicators; revenue follows as projects move through construction and delivery. H1 collections of ₹754 crore (up 77% YoY) demonstrate cash generation is real. Q1 delivered an exceptional ₹318 crore in revenue from one large project; Q2 dropped to ₹157.4 crore, suggesting project mix volatility rather than execution failure. The core question: why does a bookings surge not carry forward into revenue? Sylva, Sarjapur, and the two upcoming MMR projects are still early in their collection phase. Revenue recognition typically lags booking by 12–36 months in real estate. But Q2's -50.5% sequential revenue decline despite accelerating bookings is not explained and raises concern that approvals or construction timelines may be stretching beyond stated norms.
Management's claims: what holds up
FY27 bookings guidance revised to 70–75% growth (₹2,600–2,700 Cr)
Explicit revision: prior ₹2,100–2,200 Cr (35–40%) now ₹2,600–2,700 Cr (70–75%). Drivers: Sylva (₹500+ Cr), two MMR launches (₹2,200–2,500 Cr pipeline), Sarjapur (₹470 Cr estimated). Quantified and credible.
Supported
120% H1 bookings growth validates pricing power and market demand
H1 bookings ₹1,338 Cr (+120% YoY). Sylva booked ₹500+ Cr in 30 days at premium positioning. Market appetite is real, no contradiction.
Supported
Strong collections (₹754 Cr H1, +77% YoY) demonstrate cash generation
Collections ₹754 Cr H1 vs ₹425 Cr prior year (77% growth). Sustenance portfolio holds (~₹300 Cr H1); new project collections accelerating. Cash is genuine.
Supported
Normalized PAT margin is 22–25% EBITDA (implying 18–22% PAT)
Q2 delivered 14.4% PAT margin. H1 blended 25.3% due to Q1 exceptional project. Current tapering from Q1 (32.5% implied PAT) to Q2 (14.4%) is sharp. Guidance appears conservative or Q1 was a one-off.
Slightly overstated
Revenue conversion lag is expected; project cycle is 3–5 years
H1 gap of 2.8x is material. But Q2 -50.5% QoQ revenue despite bookings accelerating is unexplained and suggests project mix timing issues or collection delays beyond stated norms.
Partially contradicted
What changed on this call
Bookings guidance nearly doubled: Prior full-year FY27 guidance of 35–40% growth (₹2,100–2,200 Cr) upgraded to 70–75% (₹2,600–2,700 Cr). This reflects management's confidence in new launches. Regional rebalancing: Bengaluru now 50% of H1 sales (up from 30% prior year), driven by Sylva. MMR now a core third market with two projects in approval-to-launch phase. Project pipeline visibility: Sylva (₹500+ Cr booked immediately), Sarjapur (₹470 Cr estimated GDV), two MMR launches (₹2,200–2,500 Cr pipeline). Most concrete forward pipeline disclosed to date. Capex acceleration: Business development spend doubled; BD locked at ₹3,100 Cr (Sep 2026), targeting ₹4,000–5,000 Cr by FY27-end. Construction capex also doubled, but management avoided specifying absolute numbers. This opacity raised analyst concerns on leverage trajectory. The critical new concern: Sequential revenue decline. Q2 revenue at ₹157.4 Cr is -50.5% from Q1's ₹318 Cr, despite bookings accelerating. This cliff is not explained and suggests project mix volatility or timing uncertainty.
120% H1 bookings growth; Sylva ₹500 Cr in 30 days validates premium positioning
Strong collections (₹754 Cr H1, +77% YoY); cash generation is real
Multi-city footprint (Ahmedabad, Bengaluru, MMR) diversifies revenue risk
25% IRR hurdle discipline and 70–30 JD-to-outright split show capital discipline
FY27 bookings guidance quantified and credible (₹2,600–2,700 Cr)
2.8x bookings-revenue gap in H1; presales not converting at expected pace
Q2 revenue -50.5% QoQ despite bookings accelerating; conversion gap widens
Customer concentration: Sylva ₹500 Cr + Sarjapur ₹470 Cr = ~₹1,000 Cr lumpy pipeline
Capex doubling with no absolute numbers disclosed; leverage trajectory opaque
Margin guidance 22–25% EBITDA vs. current 41.5% H1; implies 19.5pp compression
Management deflecting on specifics (capex, exact margin timeline)
Revenue conversion lag persists or widens
HighH1 bookings-to-revenue ratio of 2.8x is material. If Q3/Q4 conversion ratio doesn't improve, presales could accumulate as unfulfilled liabilities, forcing guidance miss and margin compression.
Project execution slips (Sylva, Sarjapur, MMR concurrent launches)
HighFour major concurrent projects in design-to-launch. Any delay in approval (7–9 month cycle) or construction impacts presales and revenue recognition. Concentration on few projects means one slip = material impact.
Customer concentration: Sylva and Sarjapur dominate pipeline
MediumSylva (₹500+ Cr booked, ~60% of Bengaluru by value) and Sarjapur (₹470 Cr estimated) represent ~₹1,000 Cr of H2 FY27 / H1 FY28 pipeline. Underperformance in either project would materially pressure full-year targets.
Margin compression vs. guidance: 22–25% EBITDA implies 19.5pp contraction from current H1
MediumCurrent H1 EBITDA margin 41.5%, guided 22–25%. Q2 actual 14.4% PAT margin. If realized margins stabilize at 14–16% PAT, FY27 earnings growth will disappoint despite bookings surge.
Leverage tightens if capex accelerates and bookings conversion slows
MediumDebt/equity 0.26 appears safe, but BD spend doubling to ₹4,000–5,000 Cr annual run-rate + construction capex 'doubled' could tighten leverage if presales-to-collections conversion lags.
How the street is positioned
Price action and technicals: Stock closed at ₹605 (November 9, 2026). Up 24.28% from the 52-week low (₹486.8) but down 40.98% from its all-time high (₹1,025). Trading above SMA20 (₹592.35), SMA50 (₹602.48), and SMA200 (₹590.46)—all bullish. RSI at 53.3 is neutral—neither overbought nor oversold. The stock is in a bull market but well off its peak; the drawdown reflects market skepticism on execution despite upside guidance.
Institutional positioning: FII ownership eroded from 1.60% (Q1 FY25) to 0.69% (Q1 FY27)—a concerning 91 basis point drain despite upside bookings guidance. DII ownership steady at ~8–9% most recent quarters. Promoter ownership stable at 53.8%. The FII trim is a red flag: foreign institutions are reducing exposure into bullish fundamentals, suggesting skepticism on execution risk. This contrarian signal (institutions selling into upside) warrants attention.
Bulk and block activity: Recent bulk deals (Aug–Sep 2026) show tactical trading: MICROCURVES, QE SECURITIES, and NK SECURITIES alternating buys/sells in the ₹645–665 band. No smoking gun (no obvious insider selling near highs, no promoter trim). Activity suggests professional traders are hedging exposure rather than making a binary bet.
Reconciling market vs. fundamental reads: The market is pricing in significant upside (70–75% bookings growth, multi-city expansion, ₹500 Cr launches) but applying an execution discount. Stock down 41% from ATH, FII trim despite bullish guidance, yet technicals bullish above all SMAs—this is the market saying: 'We believe the upside story, but we don't trust execution yet.' Conviction will return when Q3 revenue shows conversion acceleration or when a major project (Sarjapur, MMR) de-risks execution.
1 · Q3 FY27 revenue and conversion ratio
Is the bookings-to-revenue lag narrowing or widening? Collections as a % of bookings is the key metric. If Q3 revenue accelerates (target: sequential growth or YoY >20%), execution risk narrative cracks. If stalls or declines, the 2.8x gap becomes the story.
2 · Sarjapur and MMR project launches and early traction
Sylva succeeded brilliantly (₹500 Cr in 30 days). Do Sarjapur (₹470 Cr estimated) and two MMR projects (₹2,200–2,500 Cr combined) validate multi-city strategy, or reveal concentration to Bengaluru/Sylva as a fluke? Early booking velocity determines whether ₹2,600–2,700 Cr FY27 guidance is achievable.
3 · FY27 capex and leverage trajectory
Management must quantify absolute construction capex and debt roadmap. Doubling BD spend + construction capex doubling with no absolute numbers is unacceptable for equity holders. Clarity by end of FY27 would restore credibility.
Arvind SmartSpaces is executing steady multi-city expansion with real upside, not a step-change transformation. The bookings story (120% YoY H1, 70–75% FY27 guidance, ₹500 Cr launches) is credible. But the revenue conversion lag (2.8x gap, Q2 -50.5% QoQ) creates material execution risk. Management has proven it can book business; now it must prove it can convert that business into revenue and margin on stated timelines. Confidence is encouraging; deflecting on capex and margin specifics in a high-leverage ramp-up is cautionary. The street's positioning (FII trim into upside guidance, stock down 41% from ATH, technicals bullish) mirrors this skepticism: upside is priced in, credibility is not yet earned. Track Q3 conversion ratio (collections/bookings) and Q3 revenue YoY growth; acceleration signals execution risk is abating. Until then, the honest rating is Hold—conviction must be earned on the numbers, not assumed on the story.